Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 11 Breast Neoplasms 8 Prostatic Neoplasms 7 Colorectal Neoplasms 7 Carcinoma, Non-Small-Cell Lung 6 Neoplasms 5 Melanoma 5 COVID-19 4 Multiple Myeloma 3 Lung Neoplasms 3 Gastrointestinal Neoplasms 3 Colonic Neoplasms 3 Carcinoma, Renal Cell 3 Unspecified Adult Solid Tumor, Protocol Specific 2 Solid Tumor 2 Recurrence 2 Rectal Neoplasms 2 Ovarian Neoplasms 2 Neoplasms, Plasma Cell 2 Neoplasm Metastasis 2 Leukemia 2 Glioblastoma 2 Cholangiocarcinoma 2 Adenocarcinoma of Lung 2 Adenocarcinoma 2 Urologic Diseases 1 Untreated Resectable Pancreatic Adenocarcinoma 1 Small Cell Lung Carcinoma 1 Sarcoma, Clear Cell 1 Sarcoma 1

Interventions

Sorafenib 222 lenvatinib 147 Bevacizumab 131 Nivolumab 87 atezolizumab 81 pembrolizumab 74 Radiosurgery 71 durvalumab 63 sintilimab 61 Oxaliplatin 60 Fluorouracil 56 Doxorubicin 47 tislelizumab 46 apatinib 45 Radiofrequency Ablation 44 Hepatectomy 43 camrelizumab 41 Leucovorin 41 Radiotherapy 40 tremelimumab 37 Magnetic Resonance Spectroscopy 36 regorafenib 34 Capecitabine 30 Immune Checkpoint Inhibitors 29 Folfox protocol 29 Cisplatin 28 cabozantinib 26 Gemcitabine 26 Cyclophosphamide 26 Ipilimumab 25

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Hepatocellular × Hydroxychloroquine × Clear all

NCT05842174 2026-04-16

TAQE

VA Office of Research and Development

Phase 1/2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡